Association between sickle cell trait and the prevalence and severity of diabetic retinopathy

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Harbi, Majed Al ^a   Khandekar, Rajiv ^a   Kozak, Igor ^a   Schatz, Patrik ^a,b  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRAOCULAR PRESSURE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PREVALENCE; PROLIFERATIVE DIABETIC RETINOPATHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SICKLE CELL TRAIT; VISUAL ACUITY; AGED; BLOOD; COMPLICATION; DIABETIC RETINOPATHY; MACULAR EDEMA; METABOLISM; MIDDLE AGED; RISK FACTOR; SAUDI ARABIA;

AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SAUDI ARABIA; SICKLE CELL TRAIT;

EID: 84978514909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159215     Document Type: Article

References (24)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. PMID: 8366922
2. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903. PMID: 7732997
3. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983. PMID: 7622004
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. PMID: 9742976
5. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulindependent diabetes mellitus. Ann Intern Med 1996; 124: 136-145. PMID: 8554206
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713. PMID: 9732337
7. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24: 1275-1279. PMID: 11423515
8. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244. doi: 10. 1056/NEJMoa1001288 PMID: 20587587
9. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet 2008; 372: 1385-1393. doi: 10.1016/S0140-6736(08)61411-7 PMID: 18823658
10. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402. doi: 10.1016/S0140-6736(08)61412-9PMID: 18823656
11. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128. doi: 10.1016/S0140-6736(12)61728-0PMID: 23245604
12. Lemaire C, Lamarre Y, Lemonne N, Waltz X, Chahed S, Cabot F, et al. Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cell hemoglobin-C disease but not in sickle cell anemia. Clin Hemorheol Microcirc 2013; 55: 205-212. doi: 10.3233/CH-2012-1622 PMID: 23076002
13. Jackson H, Bentley CR, Hingorani M, Atkinson P, Aclimandos WA, Thompson GM. Sickle retinopathy in patients with sickle trait. Eye (Lond) 1995; 9: 589-593.
14. Diaw M, Pialoux V, Martin C, Samb A, Diop S, Faes C, et al. Sickle Cell Trait Worsens Oxidative Stress, Abnormal Blood Rheology, and Vascular Dysfunction in Type 2 Diabetes. Diabetes Care 2015; 38: 2120-2127. doi: 10.2337/dc15-0699 PMID: 26324331
15. Bleyer AJ, Reddy SV, Sujata L, Russell GB, Akinnifesi D, Bleyer AJ Jr, et al. Sickle cell disorder and development of microvascular complications in diabetes mellitus. Clin J Am Soc Nephrol 2010; 5: 1015-1020. doi: 10.2215/CJN.08841209 PMID: 20299376
16. El-Bab MF, Shawky N, Al-Sisi A, Akhtar M. Retinopathy and risk factors in diabetic patients from Al-Madinah Al-Munawarah in the Kingdom of Saudi Arabia. Clin Ophthalmol 2012; 6: 269-276. doi: 10. 2147/OPTH.S27363 PMID: 22368446
17. Khan AR, Wiseberg JA, Lateef ZA, Khan SA. Prevalence and determinants of diabetic retinopathy in Al Hasa region of Saudi Arabia: primary health care centre based cross-sectional survey, 2007-2009.Middle East Afr J Ophthalmol 2010; 17: 257-263. doi: 10.4103/0974-9233.65502 PMID: 20844683
18. Gálvez-Ruiz A, Schatz P. Prevalence of Diabetic Retinopathy in a Population of Diabetics From the Middle East With Microvascular Ocular Motor Palsies.J Neuroophthalmol. 2016; 36: 131-133. doi: 10. 1097/Wno. 0000000000000329 PMID: 27183294
19. Wellems TE, Hayton K, Fairhurst RM. The impact of malaria parasitism: from corpuscles to communities. J Clin Invest 2009; 119: 2496-2505. doi: 10.1172/JCI38307 PMID: 19729847
20. Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med 2011; 31: 289-293. doi: 10.4103/0256-4947.81540 PMID: 21623060
21. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 2015; 314: 2137-2146. doi: 10.1001/jama.2015.15217 PMID: 26565927
22. Kopplin LJ, Igo RP Jr, Wang Y, Sivakumaran TA, Hagstrom SA, Peachey NS, et al. Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration. Genes Immun 2010; 11: 609-621. doi: 10.1038/gene.2010.39 PMID: 20861866
23. Han SZ, Zhang SH, Li R, Zhang WY, Li Y. The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int J Immunogenet 2006; 33: 281-287. PMID: 16893393
24. Lee BS, Jayathilaka GD, Huang JS, Vida LN, Honig GR, Gupta S. Analyses of in vitro nonenzymatic glycation of normal and variant hemoglobins by MALDI-TOF mass spectrometry. J Biomol Tech 2011; 22: 90-94. PMID: 21966256